CMS will transition to new eCQMs reporting standard in 2019

CMS quality programs will require the use of a new health IT standard, called Clinical Quality Language (CQL), in the 2019 care year to “better express logic defining measure populations to improve the accuracy and clarity” of electronic clinical quality measures (eCQMs).

CQL is a Health Level Seven (HL&) standard which “aims to unify the expression of logic for eCQMS and clinical decision support” domains, CMS said. The transition will begin with the 2019 reporting period for eligible hospitals and critical access hospitals (CAHs) and the 2019 performance for professionals and clinicians, affecting programs like:

  • Hospital Inpatient Quality Reporting Program
  • Medicare Electronic Health Record Incentive Program
  • Quality Payment Program, including Merit-based Incentive Payment System (MIPS) and Advanced Alternative Payment Models

CMS expects to publish CQL-based quality measures in spring 2018. Draft eCQM specifications are available until Nov. 13 for hospitals and clinicians, but those are for informational review only and can change before performance or reporting for CMS programs in 2019.

“Measures expressed using CQL logic will continue to use the Quality Data Model (QDM) as the conceptual model to express clinical concepts contained within quality measures,” CMS said. “Refer to the QDM v5.3 annotated version and current version of the CQL standard to better understand how they work together to provide eCQMs that are human readable, yet structured for electronic processing.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.